secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonnet BioTherapeutics Holdings, Inc. (—)
CIK:        0001106838
Form:       8-K
Filed at:   2025-12-03T23:59:59+00:00
Accession:  0001493152-25-025884
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 3.02, 5.01, 5.02, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonnet BioTherapeutics closes business combination with Hyperliquid Strategies; HSI to trade as PURR
--------------------------------------------------------------------------------

- Exchange ratio: each Sonnet share becomes one-fifth HSI share plus one CVR; PIPE of 239.9M shares at $1.25 closed pre-closing.
- HSI common stock begins trading on Nasdaq as "PURR" on Dec 3; Sonnet stock delisted.
- David Schamis named CEO of HSI; board includes Bob Diamond, Jeff Tuder, Eric Rosengren, Thomas King, Larry Leibowitz, Nailesh Bhatt, Albert Dyrness.
- HSI to operate as a HYPE digital asset treasury reserve company, focusing on token accumulation and yield optimization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106838/000149315225025884/0001493152-25-025884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106838/000149315225025884/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-025884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer